Lipid nanoparticles targeting tumor-associated macrophages, co-delivery method and application in tumor immunotherapy

By designing lipid nanoparticles (ipLNPs) that target tumor-associated macrophages, we achieved highly efficient targeted delivery to CD206+M2 tumor-associated macrophages and synergistically delivered multiple nucleic acid molecules, restoring T cell function, enhancing the anti-tumor ability of macrophages, and reshaping the tumor microenvironment. This solved the problems of insufficient targeting and multifunctional delivery in existing technologies, and significantly improved the efficacy of immunotherapy.

CN122234220APending Publication Date: 2026-06-19THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610338216.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-19
Publication Date
2026-06-19

AI Technical Summary

Technical Problem

Existing technologies cannot achieve precise targeted delivery to tumor-associated macrophages in solid tumors and lack the ability to synergistically deliver multifunctional nucleic acids, resulting in poor immunotherapy efficacy. Existing lipid nanoparticle systems have insufficient targeting in the tumor microenvironment and are unable to simultaneously relieve immunosuppression, improve immune infiltration, and reshape the tumor microenvironment.

Method used

A lipid nanoparticle (ipLNP) targeting tumor-associated macrophages was designed. By assembling SM-102, cholesterol, DSPC, and DSPE-PEG2000-Mannose in a specific ratio, it achieves efficient targeted delivery to CD206+M2 tumor-associated macrophages. Simultaneously, it loads anti-PD-L1 antibody-encoded mRNA, HER2-CAR mRNA, and FN1 gene-targeting sgRNA, realizing the synergistic delivery of multifunctional nucleic acids and gene editing.

Benefits of technology

It achieves precise regulation of tumor-associated macrophages, restores T cell function, enhances the anti-tumor ability of macrophages, reshapes the tumor microenvironment, significantly improves the efficacy of immunotherapy, and reduces off-target toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of nanocarrier and immunotherapy technology, specifically relating to a lipid nanoparticle targeting tumor-associated macrophages, a combined delivery method, and its application in tumor immunotherapy. The lipid nanoparticles targeting CD206 tumor-associated macrophages constructed in this invention are used for efficient in vivo delivery of multifunctional nucleic acid molecules, achieving immune regulation, gene editing, and anti-tumor therapy. This invention achieves targeted delivery and multifunctional synergistic effects through lipid particle design, nucleic acid sequence design, and in vitro and in vivo functional verification. Through in vivo delivery of ipLNPs, macrophages can simultaneously achieve: 1) expression of anti-PD-L1 antibodies, blocking immunosuppressive signals; 2) expression of HER2-CAR structures, enhancing phagocytosis and killing ability against tumors; and 3) remodeling of the tumor immune microenvironment through CRISPR / Cas9-mediated FN1 knockout. The lipid nanoparticles constructed using this invention can solve the problem of insufficient targeting of immune cells in the tumor microenvironment by traditional LNP delivery systems.
Need to check novelty before this filing date? Find Prior Art